Activated regulatory T-cells, dysfunctional and senescent T-cells hinder the immunity in pancreatic cancer

Pancreatic cancer has one of the worst prognoses of any human malignancy and leukocyte infiltration is a major prognostic marker of the disease. As current immunotherapies confer negligible survival benefits, there is a need to better characterise leukocytes in pancreatic cancer to identify better t...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän: Sivakumar, S, Abu-Shah, E, Ahern, DJ, Arbe-Barnes, EH, Jainarayanan, AK, Mangal, N, Reddy, S, Rendek, A, Easton, A, Kurz, E, Silva, M, Soonawalla, Z, Heij, LR, Bashford-Rogers, R, Middleton, MR, Dustin, ML
Materialtyp: Journal article
Språk:English
Publicerad: MDPI 2021
Beskrivning
Sammanfattning:Pancreatic cancer has one of the worst prognoses of any human malignancy and leukocyte infiltration is a major prognostic marker of the disease. As current immunotherapies confer negligible survival benefits, there is a need to better characterise leukocytes in pancreatic cancer to identify better therapeutic strategies. In this study, we analysed 32 human pancreatic cancer patients from two independent cohorts. A multi-parameter mass-cytometry analysis was performed on 32,000 T-cells from eight patients. Single-cell RNA sequencing dataset analysis was performed on a cohort of 24 patients. Multiplex immunohistochemistry imaging and spatial analysis were performed to map immune infiltration into the tumour microenvironment. Regulatory T-cell populations demonstrated highly immunosuppressive states with high TIGIT, ICOS and CD39 expression. CD8+ T-cells were found to be either in senescence or an exhausted state. The exhausted CD8 T-cells had low PD-1 expression but high TIGIT and CD39 expression. These findings were corroborated in an independent pancreatic cancer single-cell RNA dataset. These data suggest that T-cells are major players in the suppressive microenvironment of pancreatic cancer. Our work identifies multiple novel therapeutic targets that should form the basis for rational design of a new generation of clinical trials in pancreatic ductal adenocarcinoma.